Loading organizations...
§ Private Profile · Santa Rosa, CA, USA
Medtech startup developing a next-generation catheter system for PE treatment via catheter-directed thrombolysis (CDT).
Direct Flow Medical is a Chicago, Illinois-based medical device company developing a next-generation catheter system for catheter-directed thrombolysis to treat patients suffering from pulmonary embolisms. The organization's technology personalizes lytic dosing in real time to address the limitations of current treatments for the estimated 900,000 annual pulmonary embolism cases across the United States. Operating in the preclinical stage, the enterprise is funded by Phase I Small Business Innovation Research grants from the NIH and additional capital from an undisclosed strategic medical device manufacturer. The clinical solution targets interventional cardiologists and radiologists operating in acute hospital settings, building upon initial research originating from the University of Chicago Medical Center. Direct Flow Medical was officially incorporated in 2022 by former Explorer Surgical executive Jennifer Fried, alongside interventional cardiologist Dr. Jonathan Paul and interventional radiologist Dr. Osman Ahmed.
Direct Flow Medical has raised $180.3M across 6 funding rounds.
Direct Flow Medical has raised $180.3M in total across 6 funding rounds.
Direct Flow Medical has raised $180.3M in total across 6 funding rounds.
Direct Flow Medical's investors include Johnson & Johnson Innovation, New Leaf Venture Partners, Saints Capital, VantagePoint Capital Partners, Paul LaViolette, PDL BioPharma, Lightstone Ventures, Tom Kinnear, EDF Ventures, ePlanet Capital, Foundation Medical Partners, Spray Venture Partners.
Direct Flow Medical has raised $180.3M across 6 funding rounds. Most recently, it raised $31.0M Series C in April 2016.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Apr 1, 2016 | $31M Series C | — | Johnson & Johnson Innovation, NEW Leaf Venture Partners, Saints Capital, VantagePoint Capital Partners | Announced |
| Dec 3, 2014 | $32M Debt Financing | Paul Laviolette | PDL BioPharma | Announced |
| Feb 18, 2014 | $50M Debt Financing | PDL BioPharma | — | Announced |
| Mar 1, 2012 | $280K Series U | — | Johnson & Johnson Innovation, Lightstone Ventures, NEW Leaf Venture Partners, VantagePoint Capital Partners | Announced |
| Oct 1, 2009 | $40M Series C | TOM Kinnear | Johnson & Johnson Innovation, Lightstone Ventures, NEW Leaf Venture Partners, VantagePoint Capital Partners | Announced |
| Oct 1, 2007 | $27M Series B | — | Johnson & Johnson Innovation, Lightstone Ventures, NEW Leaf Venture Partners, VantagePoint Capital Partners, EDF Ventures, EPlanet Capital, Foundation Medical Partners, Jlabs, Spray Venture Partners | Announced |
Direct Flow Medical was a medical device company specializing in innovative transcatheter aortic valve replacement (TAVR) systems designed to treat aortic stenosis. Their flagship product combined surgical heart valve materials with a unique double-ring design and an inflatable framework to minimize aortic regurgitation—a common complication in TAVR procedures—thereby improving patient outcomes and procedural safety. The system featured full repositionability, retrievability, and a low-profile delivery mechanism aimed at reducing vascular complications. Direct Flow Medical primarily served cardiovascular patients and healthcare providers seeking minimally invasive solutions for severe aortic valve disease[1][2][3].
Founded in 2004 and based in Santa Rosa, California, Direct Flow Medical emerged from a need to improve the safety and efficacy of TAVR procedures. The company’s founders and early team combined expertise in cardiovascular medicine, engineering, and device design to develop a valve system that could be precisely positioned and securely sealed without the need for rapid pacing or post-dilatation. Early proof-of-concept studies demonstrated the feasibility and safety of their percutaneous valve system, which used a novel solidifying inflation medium to maintain valve position and function[2][4]. Despite promising technology and clinical results, the company ceased operations in December 2016 after failing to secure further financing[7].
Direct Flow Medical was part of the broader trend toward minimally invasive cardiovascular interventions, specifically the rapidly growing TAVR market. Their technology addressed key limitations of existing TAVR devices by reducing complications like aortic regurgitation and improving procedural control. The timing was critical as the aging population increased demand for less invasive treatments for aortic stenosis, and the medical device industry sought innovations to improve patient safety and outcomes. Although the company ultimately closed, its technological advances contributed to the evolution of TAVR device design and influenced ongoing innovation in structural heart disease treatment[1][2][4].
While Direct Flow Medical itself is no longer operational, its pioneering approach to valve design and deployment remains relevant. Future developments in TAVR technology continue to build on concepts such as repositionability, sealing mechanisms, and delivery system refinement. The company’s legacy highlights the challenges of medical device commercialization despite strong clinical innovation. Going forward, the TAVR market will likely see continued innovation driven by patient safety, procedural efficiency, and expanding indications, areas where Direct Flow Medical had made significant contributions[1][2][7].